INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
06 févr. 2019 11h42 HE
|
Schall Law
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AxoGen, Inc. (“AxoGen” or...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Welbilt, AxoGen, Markel, and Maxar and Encourages Investors to Contact the Firm
31 janv. 2019 21h04 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Welbilt, Inc., AxoGen, Inc.,...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
30 janv. 2019 15h07 HE
|
Schall Law
LOS ANGELES, Jan. 30, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AxoGen, Inc....
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Welbilt, AxoGen, Markel, and Maxar and Encourages Investors to Contact the Firm
24 janv. 2019 20h20 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Welbilt, Inc., AxoGen, Inc.,...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
21 janv. 2019 12h55 HE
|
Schall Law
LOS ANGELES, Jan. 21, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AxoGen, Inc....
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
18 janv. 2019 11h39 HE
|
Schall Law
LOS ANGELES, Jan. 18, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AxoGen, Inc....
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AxoGen, Inc. (AXGN) and Encourages AXGN Investors to Contact the Firm
09 janv. 2019 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on...
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
03 janv. 2019 10h15 HE
|
Schall Law
LOS ANGELES, Jan. 03, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AxoGen, Inc....
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
27 déc. 2018 13h10 HE
|
Schall Law
LOS ANGELES, Dec. 27, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AxoGen, Inc....
Bragar Eagel & Squire, P.C. is Investigating AxoGen, Inc. (AXGN) on Behalf of Stockholders and Encourages AXGN Investors to Contact the Firm
21 déc. 2018 17h49 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against AxoGen, Inc. (NASDAQ: AXGN). Our investigation concerns whether AxoGen has...